Robinson Jill L. 4
4 · Atlanta Braves Holdings, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Atlanta Braves (BATRK) CFO Jill Robinson Exercises Options, Sells Shares
What Happened
- Jill L. Robinson, EVP, Chief Financial Officer & Treasurer of Atlanta Braves Holdings, exercised 60,000 options on Feb 13, 2026 at a strike price of $27.18 (total exercise cost $1,630,800) and the same day disposed of 60,000 common shares in an open-market sale at $42.00 per share for total proceeds of $2,520,000. The filing also reports the derivative instrument for 60,000 options as disposed (reported at $0.00), reflecting the conversion/exercise.
Key Details
- Transaction date: 2026-02-13
- Exercise: 60,000 shares acquired at $27.18 each — total cost $1,630,800 (code M)
- Sale: 60,000 shares sold at $42.00 each — total proceeds $2,520,000 (code S)
- Footnote: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted May 15, 2025 (F1).
- Shares owned after the transaction: not disclosed in the Form 4 filing provided.
- Filing timeliness: The Form 4 was filed on 2026-02-18 for a 2026-02-13 transaction (appears to be filed after the typical 2 business‑day window).
Context
- This sequence (exercise of options followed by same‑day sale of the acquired shares) is commonly reported as a cashless exercise or immediate monetization of option value. The sale was executed under a pre-established Rule 10b5-1 plan, which is a predetermined trading arrangement and is generally treated as routine rather than a real-time expression of sentiment. The filing shows both the option exercise and the cessation/settlement of the derivative instrument.
Insider Transaction Report
Form 4
Robinson Jill L.
EVP, CFO & Treasurer
Transactions
- Exercise/Conversion
Series C Common Stock
2026-02-13$27.18/sh+60,000$1,630,800→ 139,460 total - Sale
Series C Common Stock
[F1]2026-02-13$42.00/sh−60,000$2,520,000→ 79,460 total - Exercise/Conversion
Stock option (Right to Buy) - BATRK
2026-02-13−60,000→ 30,263 totalExercise: $27.18From: 2023-12-10Exp: 2027-12-10→ Series C Common Stock (60,000 underlying)
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2025.
Signature
/s/ Greg Heller, Attorney-in-Fact|2026-02-18